The Italian National Association of Breast Surgeons (ANISC) believes that in patients with HR+HER2-/cN0-pN1 (sn) breast cancer treated with breast-conserving therapy, the preoperative work-up should be optimised to allow for a more detailed assessment of the axilla and optimise the technique of Sentinel Lymph Node Biopsy (SLNB), and that, if the surgeon deems it appropriate, routine ALND should not be considered but based on the eligibility criteria of the RxPONDER and monarchE trials to determine the treatment recommendations [91]. The gene discussed is ERBB2; the disease is breast carcinoma.